Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results

 
• By Alaric DeArment

While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.

Protagonist announced Phase IIb data for an oral IL-23R antagonist partnered with J&J • Source: Shutterstock

More from Clinical Trials

More from R&D